fda warning peptides bpc 157 tb 500 not approved EVEXIAS Life Sciences filing lawsuit over fda warning unapproved peptides bpc-157

Injection Site Selection and Rotation: The abdominal area is the most common injection site for AOD-9604 due to accessibility and consistent absorption

Considering the superior bioavailability but also the lack of research regarding subcutaneous AOD-9604, experts recommend more conservative dosing protocols involving 0.2-0.5mg/daily for up to four weeks

People may wake up frequently or struggle to fall asleep, leading to daytime fatigue and, in severe cases, insomnia

And because anywhere from 1 to 5 mg can be stored, a deficiency that develops from inadequate intake or absorption can take months to years to develop 4